Biotech | December 09, 2025
AL-S Pharma shows promising Phase 2 results for its therapy in ALS treatment
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
Adverse events were similar to placebo, and no AP-101-induced antibody responses were detected
Expands bioprocessing footprint across Asia
The EMBOLD study evaluated relutrigine for patients with SCN2A and SCN8A developmental and epileptic encephalopathies
MRI is particularly valuable in pediatric care due to its non-invasive nature
Biocon will acquire the residual stake held by Mylan (Viatris) for a total consideration of US$ 815 million
Growing patent filings and tier-2 innovators reflect expanding national research base
At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits
The MUSE system offers a minimally invasive solution for treating gastroesophageal reflux disease
This relates to the manufacture and supply of Human Recombinant Insulin (rh- Insulin) and Biosimilar Pegfilgrastim Drug Substance to the United States
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Subscribe To Our Newsletter & Stay Updated
